Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination

Sponsor
Nabiqasim Industries (Pvt) Ltd
Study ID
NCT06862739
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

  • Diabetes Mellitus
  • Type 2 DM

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Empagliflozin+Linagliptin+Metformin — COMBINATION_PRODUCT
    Scarcity of local population data on triple drug combination's impact on compliance, efficacy and safety in diabetic patients

Study Details

The efficacy and safety of a triple-pill combination therapy for advanced type 2 diabetes care. The study aims to assess the impact of 3 Oral Anti Diabetic (OAD) drugs on metabolic control, patient compliance, weight management, quality of life, diabetic treatment satisfaction and frequency of hypoglycemic events by combining them into a fixed-dose single pill.

Key Dates

Start date
Oct 30, 2025
Status verified
Apr 2026
Primary completion
Apr 30, 2026
Completion
Jun 30, 2026

Study Design

Enrollment
800 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: Glem-Lin MXR Single pill combination study
    Empagliflozin (25 mg) Linagliptin (5 mg) Metformin XR (1000 mg) once daily combination therapy

Primary Outcome Measure

Changes in HbA1c levels [ Time Frame: 03 months, 06 months ]

Related Studies